MSK-IMPACT
Tumor-normal targeted DNA sequencing for comprehensive tumor profiling.
- Developer
- Memorial Sloan Kettering Cancer Center
- Intended use
- Other
- Cancer scope
- Not reported
- Specimen
- FFPE tumor tissue, Whole blood
- Molecular modality
- DNA mutation
- Current version
- Current MSK-IMPACT 505-gene configuration
- Evidence context
- 1 structured studies · 2 indexed performance results · 2 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.